Novel Hsp90 Inhibitor C086 Potently Inhibits Non-Small Cell Lung Cancer Cells As A Single Agent Or In Combination With Gefitinib
Authors Wang L, Fan Y, Mei H, Liu Y, Zhang L, Xu J, Huang X
Received 16 May 2019
Accepted for publication 29 August 2019
Published 16 October 2019 Volume 2019:11 Pages 8937—8945
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Eileen O'Reilly
Liman Wang,1–3,* Yingjuan Fan,1,* Hanhao Mei,1 Yang Liu,1 Lianru Zhang,4 Jianhua Xu,1 Xuhui Huang2,3
1Institute of Materia Medica, School of Pharmacy, Fuijan Provincial Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, Fuzhou 350122, People’s Republic of China; 2Department of Pharmacy, Fujian Provincial Hospital Jinshan Branch/Fujian Provincial Hospital South Branch, Fuzhou 350028, People’s Republic of China; 3Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350000, People’s Republic of China; 4State Key Laboratory of Cellular Stress Biology, School of Life Science, Xiamen University, Xiamen 361005, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jianhua Xu
Institute of Materia Medica, School of Pharmacy, Fuijan Provincial Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, No. 1, Xue Fu Bei Road, University Town, Fuzhou 350122, People’s Republic of China
Tel/Fax +86 133 3844 0289
Purpose: Inhibition of heat shock protein 90 (Hsp90) can lead to degradation of multiple client proteins, which are involved in tumor progression. Elevated Hsp90 expression has been linked to poor prognosis in patients with non-small cell lung cancer (NSCLC). Discovery of effective drug is a promising strategy to improve patient survival. This study aims to investigate the synergistic antitumor mechanism of C086 combined with gefitinib in NSCLC cells in vitro.
Methods: The binding of C086, gefitinib, and the combinations to Hsp90 was characterized by ﬂuorescence quenching experiments. The inhibition of A549 or NCI-H1975 cell proliferation and apoptosis by C086 and gefitinib as a single agent or in combinations were performed using CFSE staining assays, AnnexinV–APC/PI and Western blot.
Results: C086 alone or with gefitinib reduces proliferation and increases proapoptotic caspase activation of both wild-type and mutation NSCLC, with NCI-H1975 cells showing much greater sensitivity to C086 and the combinations than A549 cells. The combination of C086 and gefitinib showed synergistic reduction of EGFR expression and the downstream PI3K/Akt and Ras-Raf-Erk pathways enhanced suppression of Erk signaling.
Conclusion: C086 combined gefitinib has a good synergistic antitumor effect in vitro. Therefore, the combination of C086 and gefitinib may provide a new theoretical basis and ideas for the treatment of NSCLC patients.
Keywords: C086, Hsp90 inhibitor, EGFR, non-small cell lung cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]